JMS logo

Japanese

JMS logo

  1. HOME
  2. Investor Relations
  3. Management Policy
  4. President’s Message

Management Policy

President’s Message

Representative Director

We would like to thank our shareholders for their continued support.

During the current interim consolidated accounting period, in Japan, sales of Closed Drug Mixing/Infusion Systems, which are being promoted as a priority business, and Infusion Pumps increased. Overseas, sales of mainstay Apheresis Kits and Blood Bags increased, while sales of Hemodialysis Machines for China and AV Fistula Needles for North America decreased.

As a result, net sales increased by 175 million yen compared with the previous interim consolidated accounting period, to 32,391 million yen (up 0.5% year-over-year).

Regarding profits, despite increases in raw material costs and personnel costs, operating profit was 9 million yen (compared with an operating loss of 19 million yen in the previous interim consolidated accounting period), due to the effect of increased sales of mainstay products. In addition, as a result of recording foreign exchange losses, ordinary loss was 145 million yen (compared with an ordinary loss of 46 million yen in the previous interim consolidated accounting period). After adjusting for corporate income taxes, etc., quarterly net loss attributable to owners of the parent was 262 million yen (compared with a quarterly net loss attributable to owners of the parent of 190 million yen in the previous interim consolidated accounting period).

In accordance with our basic policy on profit distribution, we have decided to pay a dividend of 8.5 yen per share.

We would like to ask our shareholders for their continued support and cooperation.

November 2026

JMS CO.,LTD Hiroaki Okukubo, President and Representative Director